Cargando…

In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study

Introduction Triple-negative breast cancer (TNBC) comprises a heterogeneous group of tumors with a single trait in common: an evident aggressive nature with higher rates of relapse and lower overall survival in the metastatic context when compared to other subtypes of breast cancer. To date, not a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Passos, Ioannis D, Papadimitriou, Dimochristos, Katsouda, Areti, Papavasileiou, Georgios E, Galatas, Apostolos, Tzitzis, Panagiotis, Mpakosi, Alexandra, Mironidou- Tzouveleki, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500968/
https://www.ncbi.nlm.nih.gov/pubmed/37719631
http://dx.doi.org/10.7759/cureus.43534
_version_ 1785106029283901440
author Passos, Ioannis D
Papadimitriou, Dimochristos
Katsouda, Areti
Papavasileiou, Georgios E
Galatas, Apostolos
Tzitzis, Panagiotis
Mpakosi, Alexandra
Mironidou- Tzouveleki, Maria
author_facet Passos, Ioannis D
Papadimitriou, Dimochristos
Katsouda, Areti
Papavasileiou, Georgios E
Galatas, Apostolos
Tzitzis, Panagiotis
Mpakosi, Alexandra
Mironidou- Tzouveleki, Maria
author_sort Passos, Ioannis D
collection PubMed
description Introduction Triple-negative breast cancer (TNBC) comprises a heterogeneous group of tumors with a single trait in common: an evident aggressive nature with higher rates of relapse and lower overall survival in the metastatic context when compared to other subtypes of breast cancer. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard treatment. In the present experimental study, we examine the effects of the chemotherapeutic docetaxel and the bcr/abl kinase inhibitor dasatinib on TNBC cell lines (in vitro) and on TNBC tumor xenograft mouse models (in vivo). Materials and methods TNBC cell lines were cultivated and treated with various concentrations of docetaxel and dasatinib (5 nM to 100 nM). Cell death and apoptosis were studied by flow cytometry. TNBC cell lines were then injected in BALB/c athymic nude mice to express the tumor in vivo. Four groups of mice were created (group A: control; group B: DOC; group C: DAS; group D: DOC + DAS) and treated, respectively, with the drugs and their combination. Tumors were obtained, maintained in a 10% formaldehyde solution, embedded in paraffin, and sent for further histological evaluation (hematoxylin-eosin staining and immune-histochemical analysis) to assess the tumor growth inhibition. Results The cytotoxic effects of docetaxel seem statistically important, with little effect on apoptosis. The effect of dasatinib in vitro and vivo is statistically important, in terms of apoptosis and tumor reduction, with little adverse effects. Conclusions TNBC is a difficult-to-treat oncologic condition, even in an experimental setting. Promising results concerning the addition of targeted therapies (dasatinib) to the conventional cytotoxic ones (docetaxel) have been shown, awaiting further evaluation.
format Online
Article
Text
id pubmed-10500968
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105009682023-09-15 In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study Passos, Ioannis D Papadimitriou, Dimochristos Katsouda, Areti Papavasileiou, Georgios E Galatas, Apostolos Tzitzis, Panagiotis Mpakosi, Alexandra Mironidou- Tzouveleki, Maria Cureus Pathology Introduction Triple-negative breast cancer (TNBC) comprises a heterogeneous group of tumors with a single trait in common: an evident aggressive nature with higher rates of relapse and lower overall survival in the metastatic context when compared to other subtypes of breast cancer. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard treatment. In the present experimental study, we examine the effects of the chemotherapeutic docetaxel and the bcr/abl kinase inhibitor dasatinib on TNBC cell lines (in vitro) and on TNBC tumor xenograft mouse models (in vivo). Materials and methods TNBC cell lines were cultivated and treated with various concentrations of docetaxel and dasatinib (5 nM to 100 nM). Cell death and apoptosis were studied by flow cytometry. TNBC cell lines were then injected in BALB/c athymic nude mice to express the tumor in vivo. Four groups of mice were created (group A: control; group B: DOC; group C: DAS; group D: DOC + DAS) and treated, respectively, with the drugs and their combination. Tumors were obtained, maintained in a 10% formaldehyde solution, embedded in paraffin, and sent for further histological evaluation (hematoxylin-eosin staining and immune-histochemical analysis) to assess the tumor growth inhibition. Results The cytotoxic effects of docetaxel seem statistically important, with little effect on apoptosis. The effect of dasatinib in vitro and vivo is statistically important, in terms of apoptosis and tumor reduction, with little adverse effects. Conclusions TNBC is a difficult-to-treat oncologic condition, even in an experimental setting. Promising results concerning the addition of targeted therapies (dasatinib) to the conventional cytotoxic ones (docetaxel) have been shown, awaiting further evaluation. Cureus 2023-08-15 /pmc/articles/PMC10500968/ /pubmed/37719631 http://dx.doi.org/10.7759/cureus.43534 Text en Copyright © 2023, Passos et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pathology
Passos, Ioannis D
Papadimitriou, Dimochristos
Katsouda, Areti
Papavasileiou, Georgios E
Galatas, Apostolos
Tzitzis, Panagiotis
Mpakosi, Alexandra
Mironidou- Tzouveleki, Maria
In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
title In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
title_full In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
title_fullStr In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
title_full_unstemmed In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
title_short In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
title_sort in vitro and in vivo effects of docetaxel and dasatinib in triple-negative breast cancer: a research study
topic Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500968/
https://www.ncbi.nlm.nih.gov/pubmed/37719631
http://dx.doi.org/10.7759/cureus.43534
work_keys_str_mv AT passosioannisd invitroandinvivoeffectsofdocetaxelanddasatinibintriplenegativebreastcanceraresearchstudy
AT papadimitrioudimochristos invitroandinvivoeffectsofdocetaxelanddasatinibintriplenegativebreastcanceraresearchstudy
AT katsoudaareti invitroandinvivoeffectsofdocetaxelanddasatinibintriplenegativebreastcanceraresearchstudy
AT papavasileiougeorgiose invitroandinvivoeffectsofdocetaxelanddasatinibintriplenegativebreastcanceraresearchstudy
AT galatasapostolos invitroandinvivoeffectsofdocetaxelanddasatinibintriplenegativebreastcanceraresearchstudy
AT tzitzispanagiotis invitroandinvivoeffectsofdocetaxelanddasatinibintriplenegativebreastcanceraresearchstudy
AT mpakosialexandra invitroandinvivoeffectsofdocetaxelanddasatinibintriplenegativebreastcanceraresearchstudy
AT mironidoutzouvelekimaria invitroandinvivoeffectsofdocetaxelanddasatinibintriplenegativebreastcanceraresearchstudy